LOGIN OR REGISTER
Course Library

Advances in NSCLC From Clinical Research to Clinical Practice

Hematology-Oncology
Curriculum:
Advances in NSCLC: From Clinical Research to Clinical Practice
Credits:
1.25 AMA PRA Category 1 Credit(s) ™
Launch Date:
May 07, 2015
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Physicians, Nurse Practitioners, Physician Assistants

Relevant Terms:

Lung cancer, non-small cell

Daniel Morgensztern, MD

Daniel Morgensztern, MD
Associate Professor of Medicine
Washington University School of Medicine
St. Louis, Missouri

Dr. Daniel Morgensztern is associate professor in the Division of Medical Oncology and director of Thoracic Oncology Clinical Research at the Washington University School of Medicine in St. Louis, Missouri. Dr. Morgensztern received his medical degree from Technical-Educational Foundation Souza Marques School of Medicine in Brazil. He completed his residency at the State University of Rio de Janeiro in Brazil and the University of Miami in Florida as well as a fellowship in hematology-oncology at the University of Miami.
 
Dr. Morgensztern has 10 years of experience in academic medicine, with two funded projects and several publications. His main areas of interest include outcomes research, development of new targets for the treatment of lung cancer, preclinical models for drug sensitivity, epidemiology, genomics, and immunotherapy. 
 

Jared Weiss, MD

Jared Weiss, MD
Associate Professor of Medicine
Division of Hematology and Oncology
University of North Carolina Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina

Dr. Jared Weiss is an assistant professor of medicine at the University of North Carolina (UNC) School of Medicine as well as the co-chair of the protocol review committee and faculty expert advisor for finance for the clinical protocol office at the UNC Lineberger Comprehensive Cancer Center. Dr. Weiss majored in neuroscience at Brown University and earned his medical degree at Yale University. He completed his residency at the Beth Israel Deaconess Medical Center at Harvard University and a hematology and oncology fellowship at the University of Pennsylvania, where he was mentored by Dr. Corey Langer.
 
Dr. Weiss has published numerous articles in peer reviewed journals and has delivered numerous grand rounds and CME lectures. He has designed and written multiple national clinical trials, which he now runs, for head/neck cancer and lung cancer. Particular areas of interest include neoadjuvant chemotherapy, immunotherapy, and the management of acquired resistance to targeted therapies.  Dr. Weiss is particularly proud of his roles as vice president of the Global Resource for Advancing Cancer Education and as a board member of the Lung Cancer Initiative of North Carolina.

Sarah B Goldberg MD, MPH

Sarah B Goldberg MD, MPH
Assistant Professor of Internal Medicine
Medical Oncology
Yale Cancer Center
New Haven, Connecticut

​Dr. Sarah Goldberg is an assistant professor of medicine in the division of Medical Oncology at the Yale School of Medicine and Yale Cancer Center, where she primarily treats patients with thoracic malignancies. Dr. Goldberg received her medical degree from Mount Sinai School of Medicine in New York. She completed her residency at Massachusetts General Hospital and her fellowship at Dana-Farber Cancer Institute and Massachusetts General Hospital in Boston, Massachusetts. She received her Master of Public Health in clinical effectiveness from Harvard University.
 
Dr. Goldberg is board certified in internal medicine and medical oncology. Her research interests include personalized medicine and immunotherapy for non-small cell lung cancer and identification of biomarkers that predict response to treatment.
 
 
 
1. Select, interpret, and apply new genetic and genomic tests in order to diagnose NSCLC and help guide targeted treatment decisions at the onset of care based on therapies' mechanisms of action
2. Implement the most effective new and emerging personalized treatment strategies for patients with advanced NSCLC based on efficacy and safety data for targeted therapies as well as individual patient needs and comorbidities
3. Prevent and manage disease- and treatment-related side effects in order to increase treatment tolerability and improve outcomes for patients

PHYSICIAN CONTINUING EDUCATION
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI, LLC. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
 
Credit Designation
Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
 
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
  • Daniel Morgensztern, MD, has affiliations with Celgene (Consulting) and Boehringer Ingelheim (Speaker).
  • Jared Weiss, MD, has affiliations with AstraZeneca (Consulting), and Acceleron, Celgene, GlaxoSmithKline, MedImmune, and Pfizer (Research).
  • Sarah B Goldberg MD, MPH, has affiliations with Clovis Oncology (Consulting) and AstraZeneca (Research).
RMEI, LLC
  • Boris Rozenfeld, MD, has no affiliations with commercial interests to disclose.
  • Amy Reeve has no affiliations with commercial interests to disclose.
Postgraduate Institute for Medicine
  • Judi Smelker-Mitchek, RN, BSN, has no affiliations with commercial interests to disclose.
  • Trace Hutchison, PharmD, has no affiliations with commercial interests to disclose.
  • Samantha Mattiucci, PharmD, CCMEP, has no affiliations with commercial interests to disclose.
  • Jan Schultz, RN, MSN, CCMEP, has no affiliations with commercial interests to disclose.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
 
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
 
Estimated time to complete: 1.25 hour
Medium: Internet

FEE INFORMATION
There is no fee for this educational activity.

COMMERCIAL SUPPORT
This activity is supported by an independent educational grant from Genentech.

HOW TO RECEIVE CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and physician assistants are entitled to receive up to 1.25 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:
 
  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the post-test and activity evaluation.
Physicians, nurse practitioners, and physician assistants who successfully complete the post-test and evaluation will receive CME/CE credit. You must score 70% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
 
COURSE VIEWING REQUIREMENTS
Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above

For video playback, install the latest version of Flash or Quicktime.		 Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above



 

Schedule an event with a Standardized Patient
×